Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm|Triple-Negative Breast Carcinoma|Unresectable Malignant Solid Neoplasm
Interventions: DRUG: BET Bromodomain Inhibitor ZEN-3694|DRUG: Binimetinib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging
Sponsor: National Cancer Institute (NCI)